Serum  ||| S:0 E:6 ||| JJ
anti-endometrial  ||| S:6 E:23 ||| JJ
antibodies  ||| S:23 E:34 ||| NNS
and  ||| S:34 E:38 ||| CC
first  ||| S:38 E:44 ||| JJ
trimester  ||| S:44 E:54 ||| JJ
pregnancy  ||| S:54 E:64 ||| NN
loss  ||| S:64 E:69 ||| NN
Serum  ||| S:69 E:75 ||| NNP
anti-endometrial  ||| S:75 E:92 ||| JJ
antibodies  ||| S:92 E:103 ||| NNS
( ||| S:103 E:104 ||| -LRB-
AEA ||| S:104 E:107 ||| NNP
)  ||| S:107 E:109 ||| -RRB-
have  ||| S:109 E:114 ||| VBP
been  ||| S:114 E:119 ||| VBN
studied  ||| S:119 E:127 ||| VBN
as  ||| S:127 E:130 ||| IN
a  ||| S:130 E:132 ||| DT
marker  ||| S:132 E:139 ||| NN
for  ||| S:139 E:143 ||| IN
endometriosis  ||| S:143 E:157 ||| NN
and  ||| S:157 E:161 ||| CC
implantation  ||| S:161 E:174 ||| JJ
failure ||| S:174 E:181 ||| NN
.  ||| S:181 E:183 ||| .
We  ||| S:183 E:186 ||| PRP
sought  ||| S:186 E:193 ||| VBD
to  ||| S:193 E:196 ||| TO
determine  ||| S:196 E:206 ||| VB
if  ||| S:206 E:209 ||| IN
the  ||| S:209 E:213 ||| DT
presence  ||| S:213 E:222 ||| NN
of  ||| S:222 E:225 ||| IN
AEA  ||| S:225 E:229 ||| NNP
in  ||| S:229 E:232 ||| IN
the  ||| S:232 E:236 ||| DT
serum  ||| S:236 E:242 ||| NN
of  ||| S:242 E:245 ||| IN
pregnant  ||| S:245 E:254 ||| JJ
patients  ||| S:254 E:263 ||| NNS
is  ||| S:263 E:266 ||| VBZ
associated  ||| S:266 E:277 ||| VBN
with  ||| S:277 E:282 ||| IN
first  ||| S:282 E:288 ||| JJ
trimester  ||| S:288 E:298 ||| JJ
pregnancy  ||| S:298 E:308 ||| NN
loss  ||| S:308 E:313 ||| NN
including  ||| S:313 E:323 ||| VBG
complete  ||| S:323 E:332 ||| JJ
abortion ||| S:332 E:340 ||| NN
.  ||| S:340 E:342 ||| .
This  ||| S:342 E:347 ||| DT
is  ||| S:347 E:350 ||| VBZ
a  ||| S:350 E:352 ||| DT
prospective  ||| S:352 E:364 ||| JJ
pilot  ||| S:364 E:370 ||| NN
case  ||| S:370 E:375 ||| NN
control  ||| S:375 E:383 ||| NN
study  ||| S:383 E:389 ||| NN
of  ||| S:389 E:392 ||| IN
30  ||| S:392 E:395 ||| CD
patients  ||| S:395 E:404 ||| NNS
presenting  ||| S:404 E:415 ||| VBG
with  ||| S:415 E:420 ||| IN
first  ||| S:420 E:426 ||| JJ
trimester  ||| S:426 E:436 ||| JJ
pregnancy  ||| S:436 E:446 ||| NN
loss  ||| S:446 E:451 ||| NN
compared  ||| S:451 E:460 ||| VBN
to  ||| S:460 E:463 ||| TO
a  ||| S:463 E:465 ||| DT
control  ||| S:465 E:473 ||| NN
group  ||| S:473 E:479 ||| NN
of  ||| S:479 E:482 ||| IN
30  ||| S:482 E:485 ||| CD
first  ||| S:485 E:491 ||| JJ
trimester  ||| S:491 E:501 ||| JJ
pregnant  ||| S:501 E:510 ||| JJ
patients  ||| S:510 E:519 ||| NNS
with  ||| S:519 E:524 ||| IN
a  ||| S:524 E:526 ||| DT
normal  ||| S:526 E:533 ||| JJ
course  ||| S:533 E:540 ||| NN
for  ||| S:540 E:544 ||| IN
the  ||| S:544 E:548 ||| DT
presence  ||| S:548 E:557 ||| NN
of  ||| S:557 E:560 ||| IN
serum  ||| S:560 E:566 ||| JJ
AEA ||| S:566 E:569 ||| NNP
.  ||| S:569 E:571 ||| .
The  ||| S:571 E:575 ||| DT
control  ||| S:575 E:583 ||| NN
group  ||| S:583 E:589 ||| NN
was  ||| S:589 E:593 ||| VBD
selected  ||| S:593 E:602 ||| VBN
using  ||| S:602 E:608 ||| VBG
propensity  ||| S:608 E:619 ||| JJ
matching  ||| S:619 E:628 ||| NN
of  ||| S:628 E:631 ||| IN
patient  ||| S:631 E:639 ||| JJ
characteristics ||| S:639 E:654 ||| NNS
.  ||| S:654 E:656 ||| .
AEA  ||| S:656 E:660 ||| NNP
assays  ||| S:660 E:667 ||| NN
were  ||| S:667 E:672 ||| VBD
performed  ||| S:672 E:682 ||| VBN
by  ||| S:682 E:685 ||| IN
a  ||| S:685 E:687 ||| DT
single  ||| S:687 E:694 ||| JJ
operator  ||| S:694 E:703 ||| NN
blinded  ||| S:703 E:711 ||| NN
to  ||| S:711 E:714 ||| TO
clinical  ||| S:714 E:723 ||| JJ
status  ||| S:723 E:730 ||| NN
of  ||| S:730 E:733 ||| IN
patients ||| S:733 E:741 ||| NNS
.  ||| S:741 E:743 ||| .
The  ||| S:743 E:747 ||| DT
mean  ||| S:747 E:752 ||| JJ
maternal  ||| S:752 E:761 ||| JJ
age  ||| S:761 E:765 ||| NN
in  ||| S:765 E:768 ||| IN
the  ||| S:768 E:772 ||| DT
study  ||| S:772 E:778 ||| NN
and  ||| S:778 E:782 ||| CC
control  ||| S:782 E:790 ||| NN
groups  ||| S:790 E:797 ||| NNS
was  ||| S:797 E:801 ||| VBD
not  ||| S:801 E:805 ||| RB
statistically  ||| S:805 E:819 ||| RB
significant  ||| S:819 E:831 ||| JJ
( ||| S:831 E:832 ||| -LRB-
26.1  ||| S:832 E:837 ||| CD
+ ||| S:837 E:838 ||| CD
/ ||| S:838 E:839 ||| CD
-  ||| S:839 E:841 ||| :
5.7  ||| S:841 E:845 ||| CD
vs.  ||| S:845 E:849 ||| IN
24.2  ||| S:849 E:854 ||| CD
+ ||| S:854 E:855 ||| CD
/ ||| S:855 E:856 ||| CD
-  ||| S:856 E:858 ||| :
4.5  ||| S:858 E:862 ||| CD
years ||| S:862 E:867 ||| NNS
,  ||| S:867 E:869 ||| ,
p  ||| S:869 E:871 ||| CD
< ||| S:871 E:873 ||| SYM
0.155 ||| S:873 E:878 ||| CD
) ||| S:878 E:879 ||| -RRB-
.  ||| S:879 E:881 ||| .
A  ||| S:881 E:883 ||| DT
history  ||| S:883 E:891 ||| NN
of  ||| S:891 E:894 ||| IN
pregnancy  ||| S:894 E:904 ||| NN
loss  ||| S:904 E:909 ||| NN
was  ||| S:909 E:913 ||| VBD
not  ||| S:913 E:917 ||| RB
significantly  ||| S:917 E:931 ||| RB
greater  ||| S:931 E:939 ||| JJR
in  ||| S:939 E:942 ||| IN
the  ||| S:942 E:946 ||| DT
study  ||| S:946 E:952 ||| NN
group  ||| S:952 E:958 ||| NN
( ||| S:958 E:959 ||| -LRB-
12 ||| S:959 E:961 ||| CD
/ ||| S:961 E:962 ||| CD
30  ||| S:962 E:965 ||| CD
=  ||| S:965 E:967 ||| SYM
40.0 ||| S:967 E:971 ||| CD
% ||| S:971 E:972 ||| NN
)  ||| S:972 E:974 ||| -RRB-
as  ||| S:974 E:977 ||| RB
compared  ||| S:977 E:986 ||| VBN
to  ||| S:986 E:989 ||| TO
the  ||| S:989 E:993 ||| DT
control  ||| S:993 E:1001 ||| NN
group  ||| S:1001 E:1007 ||| NN
( ||| S:1007 E:1008 ||| -LRB-
8 ||| S:1008 E:1009 ||| CD
/ ||| S:1009 E:1010 ||| CD
30  ||| S:1010 E:1013 ||| CD
=  ||| S:1013 E:1015 ||| SYM
26.7 ||| S:1015 E:1019 ||| CD
% ||| S:1019 E:1020 ||| NN
,  ||| S:1020 E:1022 ||| ,
p  ||| S:1022 E:1024 ||| CD
< ||| S:1024 E:1026 ||| SYM
0.412 ||| S:1026 E:1031 ||| CD
) ||| S:1031 E:1032 ||| -RRB-
.  ||| S:1032 E:1034 ||| .
In  ||| S:1034 E:1037 ||| IN
both  ||| S:1037 E:1042 ||| DT
study  ||| S:1042 E:1048 ||| NN
and  ||| S:1048 E:1052 ||| CC
control  ||| S:1052 E:1060 ||| NN
groups ||| S:1060 E:1066 ||| NNS
,  ||| S:1066 E:1068 ||| ,
40 ||| S:1068 E:1070 ||| CD
%  ||| S:1070 E:1072 ||| NN
of  ||| S:1072 E:1075 ||| IN
the  ||| S:1075 E:1079 ||| DT
samples  ||| S:1079 E:1087 ||| NNS
tested  ||| S:1087 E:1094 ||| VBD
positive  ||| S:1094 E:1103 ||| JJ
for  ||| S:1103 E:1107 ||| IN
AEA ||| S:1107 E:1110 ||| NNP
;  ||| S:1110 E:1112 ||| :
therefore ||| S:1112 E:1121 ||| RB
,  ||| S:1121 E:1123 ||| ,
we  ||| S:1123 E:1126 ||| PRP
found  ||| S:1126 E:1132 ||| VBD
no  ||| S:1132 E:1135 ||| DT
evidence  ||| S:1135 E:1144 ||| NN
of  ||| S:1144 E:1147 ||| IN
an  ||| S:1147 E:1150 ||| DT
association  ||| S:1150 E:1162 ||| NN
between  ||| S:1162 E:1170 ||| IN
the  ||| S:1170 E:1174 ||| DT
presence  ||| S:1174 E:1183 ||| NN
of  ||| S:1183 E:1186 ||| IN
AEA  ||| S:1186 E:1190 ||| NNP
and  ||| S:1190 E:1194 ||| CC
pregnancy  ||| S:1194 E:1204 ||| NN
loss ||| S:1204 E:1208 ||| NN
.  ||| S:1208 E:1210 ||| .
These  ||| S:1210 E:1216 ||| DT
findings  ||| S:1216 E:1225 ||| NNS
in  ||| S:1225 E:1228 ||| IN
our  ||| S:1228 E:1232 ||| PRP$
pilot  ||| S:1232 E:1238 ||| NN
study  ||| S:1238 E:1244 ||| NN
suggest  ||| S:1244 E:1252 ||| VBP
that  ||| S:1252 E:1257 ||| DT
presence  ||| S:1257 E:1266 ||| NN
of  ||| S:1266 E:1269 ||| IN
serum  ||| S:1269 E:1275 ||| JJ
AEA  ||| S:1275 E:1279 ||| NNP
does  ||| S:1279 E:1284 ||| VBZ
not  ||| S:1284 E:1288 ||| RB
appear  ||| S:1288 E:1295 ||| VB
to  ||| S:1295 E:1298 ||| TO
be  ||| S:1298 E:1301 ||| VB
a  ||| S:1301 E:1303 ||| DT
marker  ||| S:1303 E:1310 ||| NN
for  ||| S:1310 E:1314 ||| IN
early  ||| S:1314 E:1320 ||| JJ
pregnancy  ||| S:1320 E:1330 ||| NN
loss ||| S:1330 E:1334 ||| NN
.  ||| S:1334 E:1336 ||| .
